- Home
- YSXT vs ANVS Comparison
YSXT vs ANVS Comparison
Compare YSXT & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSXT | ANVS |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | China | United States |
| Employees | 39 | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 69.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | YSXT | ANVS |
|---|---|---|
| Price | $1.04 | $1.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 24.1K | ★ 1.2M |
| Earning Date | 02-03-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.93 | $1.54 |
| 52 Week High | $9.90 | $5.50 |
Technical Indicators
Market Signals| Indicator | YSXT | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 43.64 |
| Support Level | $0.93 | $1.79 |
| Resistance Level | $1.31 | $2.57 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 14.47 | 24.29 |
Price Performance
Historical ComparisonAbout YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.